123i-ibvm

Small moleculeexperimentalImaging agent

Clinical trial activity

2 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Feb 1, 2007 (NCT00480701)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
123-iodine

Oral

No

Parenteral

No

Topical

No

Also known as

  • 123i ibvm
  • 123i ibvm
  • 123i-ibvm
  • 123i-ibvm

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00556764Early Phase 1 (Phase 1)Jul 1, 2007Department of Defense, Institute for Neurodegenerative Disorders, University of Oklahoma
NCT00480701Phase 2Feb 1, 2007Institute for Neurodegenerative Disorders
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Institute for Neurodegenerative DisordersAcademic/Hospital2222007
Department of DefenseGovernment1012007
University of OklahomaAcademic/Hospital1012007
3 organizations
Page 1 / 1